Book Description
Ovarian cancer is an umbrella term for a collection of distinct disease entities (histotypes). Until now, the majority of research has focussed on the most common histotype, high-grade serous ovarian carcinoma (HGSOC), which accounts for 70% of cases. The less common histotypes – including endometrioid, clear cell, mucinous, low-grade serous, carcinosarcoma, and non-epithelial histotypes – have received far less research attention. Accordingly, while major advances in our understanding of HGSOC have led to molecularly-directed therapies that improve patient outcomes, progress in less common histotypes has lagged behind. Notably, many of the uncommon histotypes demonstrate resistance to conventional chemotherapy regimens, and their inherent biological differences suggest most are unlikely to respond to emerging molecular therapeutics designed to target the biology of common ovarian cancer types.